{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:28:48Z","timestamp":1789032528542,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P51OD010425"],"award-info":[{"award-number":["P51OD010425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U42OD011123"],"award-info":[{"award-number":["U42OD011123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI167009"],"award-info":[{"award-number":["R01AI167009"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI158728"],"award-info":[{"award-number":["R01AI158728"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV002613"],"award-info":[{"award-number":["INV002613"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV03398"],"award-info":[{"award-number":["INV03398"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001906","name":"Washington Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001906","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41434-026-00598-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:37:23Z","timestamp":1772109443000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda\u2019s context"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2500","authenticated-orcid":false,"given":"J. Felipe","family":"Montano-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-016X","authenticated-orcid":false,"given":"Jennifer E.","family":"Adair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Bakyayita","family":"Kyeyune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Bayigga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo-Mutuluuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"598_CR1","unstructured":"Regional Committee for Africa (2011). Sickle-Cell Disease: a strategy for the WHO African Region. https:\/\/iris.who.int\/handle\/10665\/1682."},{"key":"598_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/tmi.13506","volume":"26","author":"AG Hernandez","year":"2021","unstructured":"Hernandez AG, Kiyaga C, Howard TA, Ssewanyana I, Ndeezi G, Aceng JR, et al. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Trop Med Int Health. 2021;26:23\u201332.","journal-title":"Trop Med Int Health"},{"key":"598_CR3","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2214-109X(15)00288-0","volume":"4","author":"G Ndeezi","year":"2016","unstructured":"Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, et al. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob Health. 2016;4:e195\u2013200.","journal-title":"Lancet Glob Health"},{"key":"598_CR4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40273-023-01294-3","volume":"41","author":"D Teigen","year":"2023","unstructured":"Teigen D, Opoka RO, Kasirye P, Nabaggala C, Hume HA, Blomberg B, et al. Cost-effectiveness of hydroxyurea for sickle cell anemia in a low-income African setting: a model-based evaluation of two dosing regimens. Pharmacoeconomics. 2023;41:1603\u201315.","journal-title":"Pharmacoeconomics"},{"key":"598_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3885979","volume":"2022","author":"WI Egesa","year":"2022","unstructured":"Egesa WI, Nakalema G, Waibi WM, Turyasiima M, Amuje E, Kiconco G, et al. Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. Int J Pediatr. 2022;2022:3885979.","journal-title":"Int J Pediatr"},{"key":"598_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.4102\/ajlm.v10i1.1303","volume":"10","author":"AG Hernandez","year":"2021","unstructured":"Hernandez AG, Kiyaga C, Howard TA, Ssewanyana I, Ndeezi G, Aceng JR, et al. Operational analysis of the national sickle cell screening programme in the Republic of Uganda. Afr J Lab Med. 2021;10:1303.","journal-title":"Afr J Lab Med"},{"key":"598_CR7","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462323002635","volume":"39","author":"C Mayora","year":"2023","unstructured":"Mayora C, Kazibwe J, Ssempala R, Nakimuli B, Ssennyonjo A, Ekirapa E, et al. Health technology assessment (HTA) readiness in Uganda: stakeholder\u2019s perceptions on the potential application of HTA to support national universal health coverage efforts. Int J Technol Assess Health Care. 2023;39:e65.","journal-title":"Int J Technol Assess Health Care"},{"key":"598_CR8","doi-asserted-by":"publisher","first-page":"eadn1902","DOI":"10.1126\/scitranslmed.adn1902","volume":"16","author":"KW Doxzen","year":"2024","unstructured":"Doxzen KW, Adair JE, Fonseca Bazzo YM, Bukini D, Cornetta K, Dalal V, et al. The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024;16:eadn1902.","journal-title":"Sci Transl Med"},{"key":"598_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27312-6","volume":"12","author":"M Maschan","year":"2021","unstructured":"Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021;12:7200.","journal-title":"Nat Commun"},{"key":"598_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/heapol\/czaa073","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35:107\u201314.","journal-title":"Health Policy Plan"},{"key":"598_CR11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00277-020-04233-w","volume":"99","author":"RJ Desai","year":"2020","unstructured":"Desai RJ, Mahesri M, Globe D, Mutebi A, Bohn R, Achebe M, et al. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries. Ann Hematol. 2020;99:2497\u2013505.","journal-title":"Ann Hematol"},{"key":"598_CR12","unstructured":"Ministry of Health Uganda (2023). Uganda Clinical Guidelines. Available at https:\/\/www.health.go.ug\/cause\/uganda-clinical-guidelines-2023\/."},{"key":"598_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M23-1520","volume":"177","author":"A Basu","year":"2024","unstructured":"Basu A, Winn AN, Johnson KM, Jiao B, Devine B, Hankins JS, et al. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis. Ann Intern Med. 2024;177:155\u201364.","journal-title":"Ann Intern Med"},{"key":"598_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41588-022-01257-y","volume":"55","author":"S Cancellieri","year":"2023","unstructured":"Cancellieri S, Zeng J, Lin LY, Tognon M, Nguyen MA, Lin J, et al. Human genetic diversity alters off-target outcomes of therapeutic gene editing. Nat Genet. 2023;55:34\u201343.","journal-title":"Nat Genet"},{"key":"598_CR15","unstructured":"Administration USFaD. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. In, 2023."},{"key":"598_CR16","unstructured":"Sachs, J. D. (2001). Macroeconomics and health: Investing in health for economic development. World Health Organization. Geneva, Switzerland."},{"key":"598_CR17","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2352-3026(21)00191-5","volume":"8","author":"K Esoh","year":"2021","unstructured":"Esoh K, Wonkam-Tingang E, Wonkam A. Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care. Lancet Haematol. 2021;8:e744\u2013e755.","journal-title":"Lancet Haematol"},{"key":"598_CR18","unstructured":"Thalassaemia International Federation. (2024). African health ministers launch drive to curb SCD toll. https:\/\/thalassaemia.org.cy\/news\/african-health-ministers-launch-drive-to-curb-scd-toll\/."},{"key":"598_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41434-021-00284-4","volume":"30","author":"JE Adair","year":"2023","unstructured":"Adair JE, Androski L, Bayigga L, Bazira D, Brandon E, Dee L, et al. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Ther. 2023;30:216\u201321.","journal-title":"Gene Ther"},{"key":"598_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"HK Palani","year":"2023","unstructured":"Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA, et al. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy(R): real-world experience and cost analysis in India. Bone Marrow Transpl. 2023;58:160\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"598_CR21","doi-asserted-by":"publisher","first-page":"e2014046","DOI":"10.4084\/mjhid.2014.046","volume":"6","author":"SK Sharma","year":"2014","unstructured":"Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G, et al. Cost of hematopoietic stem cell transplantation in India. Mediterranean J Hematol Infect Dis. 2014;6:e2014046.","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"598_CR22","doi-asserted-by":"publisher","first-page":"e41062","DOI":"10.1097\/MD.0000000000041062","volume":"103","author":"EI Obeagu","year":"2024","unstructured":"Obeagu EI, Obeagu GU. Living with sickle cell in Uganda: A comprehensive perspective on challenges, coping strategies, and health interventions. Med (Baltim). 2024;103:e41062.","journal-title":"Med (Baltim)"},{"key":"598_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s40273-021-01072-z","volume":"39","author":"B Jiao","year":"2021","unstructured":"Jiao B, Basu A, Roth J, Bender M, Rovira I, Clemons T, et al. The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. Pharmacoeconomics. 2021;39:1225\u201341.","journal-title":"Pharmacoeconomics"},{"key":"598_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-024-01385-9","volume":"42","author":"WL Herring","year":"2024","unstructured":"Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, et al. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States. Pharmacoeconomics. 2024;42:693\u2013714.","journal-title":"Pharmacoeconomics"},{"key":"598_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.7326\/M22-3272","volume":"176","author":"G Goshua","year":"2023","unstructured":"Goshua G, Calhoun C, Ito S, James LP, Luviano A, Krishnamurti L, et al. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Ann Intern Med. 2023;176:779\u201387.","journal-title":"Ann Intern Med"},{"key":"598_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53121-0","volume":"14","author":"G Morgan","year":"2024","unstructured":"Morgan G, Back E, Besser M, Hallett TB, Guzauskas GF. The value-based price of transformative gene therapy for sickle cell disease: a modeling analysis. Sci Rep. 2024;14:2739.","journal-title":"Sci Rep"},{"key":"598_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12955-019-1225-7","volume":"17","author":"N Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study. Health Qual Life Outcomes. 2019;17:155.","journal-title":"Health Qual Life Outcomes"},{"key":"598_CR28","first-page":"1253","volume":"29","author":"D Nikitin","year":"2023","unstructured":"Nikitin D, Beaudoin FL, Thokala P, McKenna A, Nhan E, Rind DM, et al. Gene therapies for sickle cell disease: Effectiveness and value. J Manag Care Spec Pharm. 2023;29:1253\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"598_CR29","unstructured":"MSH (Management Sciences for Health). International Medical Products Price Guide, 2015 Edition."},{"key":"598_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.12688\/wellcomeopenres.15847.2","volume":"5","author":"P Olupot-Olupot","year":"2020","unstructured":"Olupot-Olupot P, Wabwire H, Ndila C, Adong R, Ochen L, Amorut D, et al. Characterising demographics, knowledge, practices and clinical care among patients attending sickle cell disease clinics in Eastern Uganda. Wellcome Open Res. 2020;5:87.","journal-title":"Wellcome Open Res"},{"key":"598_CR31","doi-asserted-by":"publisher","first-page":"e0214355","DOI":"10.1371\/journal.pone.0214355","volume":"14","author":"N Shah","year":"2019","unstructured":"Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PloS one. 2019;14:e0214355.","journal-title":"PloS one"},{"key":"598_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02096-6","volume":"16","author":"AU Zaidi","year":"2021","unstructured":"Zaidi AU, Glaros AK, Lee S, Wang T, Bhojwani R, Morris E, et al. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease. Orphanet J Rare Dis. 2021;16:460.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00598-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:16:54Z","timestamp":1775571414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00598-1","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JA and CK-M are co-founders of the Global Gene Therapy Initiative (GGTI). JA is a Fellow of the Ugandan National Academy of Sciences (FUNAS). Work conducted for this study was performed while JA was employed at the Fred Hutchinson Cancer Center. JA is now Professor and Vice Chair of the Department of Genetic and Cellular Medicine at the University of Massachusetts Chan Medical School. FM-C and RH have assigned an innovation related to this study (Scalable Methodology for Adapting High-Income Cost-Effectiveness Evidence to Low-Resource Healthcare Settings) to the University of Washington. At the time of manuscript submission, this innovation is not protected by a patent. None of the remaining authors declare any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not involve human participants, animals, or the collection of identifiable personal data. All analyses were conducted using publicly available, previously published data sources and simulation models. All methods were performed in accordance with the relevant guidelines and regulations. Because no primary data collection involving human participants or live vertebrates was performed, approval from an ethics committee was not required, and informed consent was not applicable. No identifiable images of human research participants are included in this article; therefore, written informed consent for publication of images was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}